Endometriosis - Pipeline Review, H2 2017

Date: September 30, 2017
Pages: 131
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: EE555FFC69CEN
Leaflet:

Download PDF Leaflet

Endometriosis - Pipeline Review, H2 2017
Endometriosis - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Endometriosis - Pipeline Review, H2 2017, provides an overview of the Endometriosis (Women's Health) pipeline landscape.

Endometriosis is an often painful disorder in which tissue that normally lines the inside of uterus (endometrium) grows outside uterus (endometrial implant). Symptoms include pelvic pain, menstrual cramps, inflammation, infertility and abnormal bleeding. Risk factors age, uterine abnormalities, history of pelvic infection and family history. Treatment includes NSAIDs, birth control pills and progestins.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Endometriosis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Endometriosis (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Endometriosis (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Endometriosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 2, 9, 7, 1, 14, 5 and 4 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 4 and 3 molecules, respectively.

Endometriosis (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Endometriosis (Women's Health).
  • The pipeline guide reviews pipeline therapeutics for Endometriosis (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Endometriosis (Women's Health) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Endometriosis (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Endometriosis (Women's Health)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Endometriosis (Women's Health).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Endometriosis (Women's Health) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Endometriosis - Overview
Endometriosis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Endometriosis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Endometriosis - Companies Involved in Therapeutics Development
AbbVie Inc
Addex Therapeutics Ltd
APAvadis Biotechnologies Srl
Astellas Pharma Inc
Bayer AG
ElexoPharm GmbH
EndoCeutics Inc
Enteris BioPharma Inc
Evotec AG
Forendo Pharma Ltd
Kissei Pharmaceutical Co Ltd
Lipicard Technologies Ltd
Luye Pharma Group Ltd
Nippon Shinyaku Co Ltd
Ogeda SA
Philogen SpA
Repros Therapeutics Inc
SK Chemicals Co Ltd
Takeda Pharmaceutical Co Ltd
ValiRx Plc
Viramal Ltd
Endometriosis - Drug Profiles
acolbifene hydrochloride + GnRH Agonist + prasterone - Drug Profile
ADX-68692 - Drug Profile
BAY-1128688 - Drug Profile
BAY-1158061 - Drug Profile
BAY-1817080 - Drug Profile
BAY-1834845 - Drug Profile
danazol - Drug Profile
Drug 1 for Endometriosis - Drug Profile
Drug 2 for Endometriosis - Drug Profile
Drug 3 for Endometriosis - Drug Profile
Drug 4 for Endometriosis - Drug Profile
Drug for Endometriosis - Drug Profile
Drug to Antagonize P2X3 for Endometriosis - Drug Profile
Drug to Inhibit C-Jun for Endometriosis - Drug Profile
Drugs for Endometriosis and Uterine Fibroids - Drug Profile
EC-313 - Drug Profile
elagolix sodium - Drug Profile
fezolinetant - Drug Profile
FP-5677 - Drug Profile
goserelin ER - Drug Profile
KLH-2109 - Drug Profile
leuprolide acetate - Drug Profile
LT-6121 - Drug Profile
MIA-602 - Drug Profile
NHP-07 - Drug Profile
NS-580 - Drug Profile
opigolix - Drug Profile
Peptides for Endometriosis and Hepatic Tumor - Drug Profile
Peptides to Inhibit Aminopeptidase A for Endometriosis, Neuroblastoma and Hepatic (Liver) Tumor - Drug Profile
PGL-2001 - Drug Profile
progesterone - Drug Profile
Recombinant Protein for Endometriosis, Ovarian Hyperstimulation Syndrome and Polycystic Ovarian Syndrome - Drug Profile
relugolix - Drug Profile
SKI-2670 - Drug Profile
Small Molecule to Antagonize FSH Receptor and LH Receptor for Women's Health - Drug Profile
Small Molecules to Antagonize GnRH for Endometriosis, Male Health, Oncology and Uterine Fibroids - Drug Profile
Small Molecules to Antagonize Prostanoid EP2 and EP4 Receptors for Endometriosis - Drug Profile
Small Molecules to Inhibit 17 Beta-HSD1 for Endometriosis - Drug Profile
Small Molecules to Inhibit 17 Beta-Hydroxysteroid Dehydrogenase Type1 for Endometriosis and Estrogen Dependent Cancers - Drug Profile
Small Molecules to Inhibit CD147 for Immunology, Oncology, Endometriosis and Arthritis - Drug Profile
Small Molecules to Inhibit HSD17B1 for Endometriosis - Drug Profile
SR-16234 - Drug Profile
Stem Cell Therapy for Asherman's Syndrome and Endometrial Atrophy - Drug Profile
Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology - Drug Profile
telapristone acetate - Drug Profile
tetravil - Drug Profile
TOT-206 - Drug Profile
triptorelin acetate ER - Drug Profile
VAL-301 - Drug Profile
vilaprisan - Drug Profile
VPE-001 - Drug Profile
Endometriosis - Dormant Projects
Endometriosis - Discontinued Products
Endometriosis - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Endometriosis, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Products under Development by Companies, H2 2017 (Contd.2), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.1), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Endometriosis - Pipeline by AbbVie Inc, H2 2017
Endometriosis - Pipeline by Addex Therapeutics Ltd, H2 2017
Endometriosis - Pipeline by APAvadis Biotechnologies Srl, H2 2017
Endometriosis - Pipeline by Astellas Pharma Inc, H2 2017
Endometriosis - Pipeline by Bayer AG, H2 2017
Endometriosis - Pipeline by ElexoPharm GmbH, H2 2017
Endometriosis - Pipeline by EndoCeutics Inc, H2 2017
Endometriosis - Pipeline by Enteris BioPharma Inc, H2 2017
Endometriosis - Pipeline by Evotec AG, H2 2017
Endometriosis - Pipeline by Forendo Pharma Ltd, H2 2017
Endometriosis - Pipeline by Kissei Pharmaceutical Co Ltd, H2 2017
Endometriosis - Pipeline by Lipicard Technologies Ltd, H2 2017
Endometriosis - Pipeline by Luye Pharma Group Ltd, H2 2017
Endometriosis - Pipeline by Nippon Shinyaku Co Ltd, H2 2017
Endometriosis - Pipeline by Ogeda SA, H2 2017
Endometriosis - Pipeline by Philogen SpA, H2 2017
Endometriosis - Pipeline by Repros Therapeutics Inc, H2 2017
Endometriosis - Pipeline by SK Chemicals Co Ltd, H2 2017
Endometriosis - Pipeline by Takeda Pharmaceutical Co Ltd, H2 2017
Endometriosis - Pipeline by ValiRx Plc, H2 2017
Endometriosis - Pipeline by Viramal Ltd, H2 2017
Endometriosis - Dormant Projects, H2 2017
Endometriosis - Dormant Projects, H2 2017 (Contd.1), H2 2017
Endometriosis - Discontinued Products, H2 2017

LIST OF FIGURES

Number of Products under Development for Endometriosis, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

COMPANIES MENTIONED

AbbVie Inc
Addex Therapeutics Ltd
APAvadis Biotechnologies Srl
Astellas Pharma Inc
Bayer AG
ElexoPharm GmbH
EndoCeutics Inc
Enteris BioPharma Inc
Evotec AG
Forendo Pharma Ltd
Kissei Pharmaceutical Co Ltd
Lipicard Technologies Ltd
Luye Pharma Group Ltd
Nippon Shinyaku Co Ltd
Ogeda SA
Philogen SpA
Repros Therapeutics Inc
SK Chemicals Co Ltd
Takeda Pharmaceutical Co Ltd
ValiRx Plc
Viramal Ltd
Skip to top


Ask Your Question

Endometriosis - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: